Loading
pharma&
pharma& is a Vienna company that buys and markets established medicines, including the PARP inhibitor rucaparib (Rubraca), which it acquired from Clovis Oncology's bankruptcy in 2023.
Also called: pharmaand GmbHpharma& GmbHpharmaand
Overview
pharma& (pharmaand GmbH), based in Vienna, acquires and commercialises marketed medicines rather than developing new molecules. In oncology it bought rucaparib (Rubraca), the PARP inhibitor approved for BRCA-mutated ovarian and prostate cancer, from Clovis Oncology in 2023 after Clovis filed for bankruptcy, and it now holds the US and EU authorisations and runs the remaining trials and post-marketing commitments. It appears on OnCo as an FDA oncology applicant and a phase 3 trial sponsor on ClinicalTrials.gov.
Headquarters
Vienna, AT
Scorecard
All companies#169of 1245 companies, score 34
- approved products +6
- targets +4
- modalities +2
- regions +4
- 24-month regulatory events +4
- registry trials +14
1 approved, 0 in phase 3, 0 earlier, 2 targets, 49 registry studies. Formula on the scorecards page.
Type
Stage
Large private
Website
Products
1ApprovedSmall-molecule PARP inhibitor
Rucaparib · Rubraca
Rucaparib is a DNA-repair inhibitor for selected BRCA-mutated ovarian and prostate cancers. Its prostate indication received regular US approval in December 2025.
Connected
6Similar pages
- TrialATHENA-MONO / GOG-3020
Shares Clovis Oncology, Rucaparib, PARP, Ovarian cancer.
- TrialRucaparib with radiation after incomplete response to chemotherapy
- TreatmentDSB2455
Shares PARP, Ovarian cancer, Prostate cancer.
- TrialStudy to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Shares PARP, Ovarian cancer, Prostate cancer.
- TrialA Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
Shares PARP, Ovarian cancer, Prostate cancer.
- TrialHS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Shares PARP, Ovarian cancer, Prostate cancer.
- TrialA Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer
Shares PARP, Ovarian cancer.
- TrialPhase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
Shares PARP, Ovarian cancer, Prostate cancer.
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
pharmaand.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/